Breaks Categories: Stock Spotlights

ThursdayJun 18, 2026 12:32 pm

BioMedNewsBreaks — Why Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) Is ‘One to Watch’

Disseminated on behalf of Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) and may include paid advertising. A clinical-stage oncology company , Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) is focused on advancing a new class of DNA Damage Response (“DDR”) therapies and developing artificial intelligence-driven precision oncology solutions. “The company is leading the development of Polynucleotide Kinase Phosphatase (‘PNKP’) inhibitors, an emerging category of DDR therapeutics designed to target DNA repair pathways involved in cancer survival and resistance,” reads a recent article. “Through its dual-platform approach, Onco-Innovations combines proprietary drug development with AI-enabled technologies intended to support oncology research, clinical development, patient stratification and evidence generation.” To…

Continue Reading

WednesdayJun 17, 2026 3:30 pm

BioMedNewsBreaks — Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) Aligns with Growing Shift Toward Predictive, Precision Medicine

Cardio Diagnostics Holdings (NASDAQ: CDIO) is focused on personalized, data-driven cardiovascular care powered by artificial intelligence, epigenetics and genetic insights. “Through its proprietary platform and expanding testing capabilities, the company is pursuing a future in which prevention becomes more accessible, scalable and actionable before life-threatening cardiac events occur,” reads a recent article. “The company’s vision reflects a broader shift taking place across the healthcare industry toward predictive and precision medicine. Cardio Diagnostics envisions a healthcare system where every patient receives individualized care informed by their unique molecular insights and where heart disease is no longer the world’s leading killer. Achieving that goal…

Continue Reading

TuesdayJun 16, 2026 1:27 pm

BioMedNewsBreaks — Earth Science Tech Inc. (ETST) Positioned at Intersection of Telemedicine, Pharmacy, Healthcare Services

Earth Science Tech (OTC: ETST) was featured in a recent article that discussed its significant transformation over the past several years, positioning as a diversified holding company focused on pharmaceutical compounding, telemedicine, healthcare services, and strict capital allocation. “The company recently completed a vertically integrated telehealth and pharmacy ecosystem through the launch of MyOnlineConsultation.com, with telemedicine capabilities supporting patient acquisition, while pharmacy operations drive high-margin recurring prescription-based revenue streams,” reads a recent article. “Above all, Earth Science Tech emphasizes balance-sheet strength and capital discipline through ongoing share repurchase initiatives designed to reduce dilution and support shareholder value.” To view the full…

Continue Reading

TuesdayJun 16, 2026 1:01 pm

BioMedNewsBreaks — Why VERAXA Biotech AG (NASDAQ: VRXA) Is ‘One to Watch’

VERAXA Biotech (NASDAQ: VRXA) is advancing a diversified oncology pipeline spanning monoclonal antibodies, antibody-drug conjugates, bispecific ADCs and proprietary BiTAC-based therapeutic formats across multiple cancer indications. “The company is focused on the discovery and development of a new generation of antibody-based therapeutics for the treatment of solid tumors. VERAXA’s vision is to deliver the next wave of smart cancer therapies with curative potential and improved safety profiles,” reads a recent article. “The company is building a pipeline that includes dual-targeting antibody-drug conjugates (‘ADCs’) and T-cell engagers (‘TCEs’) predominantly based on its patented BiTAC concept. This concept is designed to improve the…

Continue Reading

FridayJun 12, 2026 2:38 pm

BioMedNewsBreaks — Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) Harnesses AI, Genetics and Epigenetics to Advance Cardiovascular Risk Detection

Cardio Diagnostics Holdings (NASDAQ: CDIO) was featured in a recent article that discusses the urgent need for more effective tools to identify risk earlier and guide personalized intervention strategies for cardiovascular disease. The piece reads, “Cardio Diagnostics is rising to the challenge by developing a suite of clinical, population health and biopharma solutions designed to leverage artificial intelligence (‘AI’), epigenetics and genetics to improve cardiovascular disease prevention, detection and management… The company’s platform is built around the integration of genetic and epigenetic biomarkers with AI-driven analytics to provide personalized cardiovascular insights from blood-based testing. Cardio Diagnostics currently offers two clinical solutions, Epi+Gen…

Continue Reading

ThursdayJun 11, 2026 2:32 pm

BioMedNewsBreaks — SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) Accelerates Development Strategy for Lead Candidate

Disseminated on behalf of SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) and may include paid advertising. SureNano Science (CSE: SURE) (OTCQB: SURNF), a Canadian life sciences company, was featured in a recent article that discussed the company’s efforts beginning a key phase of preclinical development for its lead drug candidate GEP-44, a multi-receptor peptide targeting obesity and type 2 diabetes. The publication reads, “The company is initiating a Good Laboratory Practice (‘GLP’) toxicology and pharmacology program aligned with U.S. Food and Drug Administration (‘FDA’) requirements, intended to support an Investigational New Drug (‘IND’) application and represents a necessary step before first-in-human clinical trials.…

Continue Reading

FridayMay 22, 2026 3:28 pm

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Aims to Close Critical Gap in Early Cardiac Detection

HeartBeam (NASDAQ: BEAT) is developing technology aimed at improving how cardiac conditions are identified and monitored, positioning its solutions at the intersection of rising clinical need and evolving innovation. “One of the most persistent challenges in cardiac care is pre-hospital delay, with many patients not seeking medical attention at the onset of symptoms. Traditional electrocardiogram testing is typically conducted in clinical environments, which may not coincide with the onset of symptoms such as intermittent chest pain, palpitations or other warning signs. As a result, patients often defer care and clinicians are left without the data needed to make timely, informed decisions,”…

Continue Reading

ThursdayMay 21, 2026 12:55 pm

BioMedNewsBreaks — Why SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) Is ‘One to Watch’

Disseminated on behalf of SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) and may include paid advertising. SureNano Science (CSE: SURE) (OTCQB: SURNF), a Canadian life sciences company, is positioning itself within one of the most significant pharmaceutical developments of this generation: the rapid rise of GLP-1–based therapies for obesity and metabolic disease. “Blockbuster drugs such as Ozempic(R), Wegovy(R), and Mounjaro(R) have demonstrated both strong clinical outcomes and massive commercial success, driving intense competition among large pharmaceutical companies to develop next-generation treatments,” a recent article reads. “Within this landscape, SureNano represents a smaller, more agile entrant seeking to advance its own differentiated GLP-based therapeutic.…

Continue Reading

TuesdayMay 19, 2026 2:28 pm

BioMedNewsBreaks — MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Advancing Workplace Safety with AI-Powered Technology

Disseminated on behalf of MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) and may include paid advertising. MindBio Therapeutics (CSE: MBIO) (OTCQB: MBQIF) is introducing a novel system aimed at identifying drug and alcohol impairment, initially focused on the South American mining sector, where remote operations and heavy machinery make safety monitoring critical. An article discussing this reads, “The biotechnology company, which has spent several years conducting research into intoxication detection, has developed a voice-based AI system designed to identify signs of alcohol or drug impairment within seconds, the first of its kind in the world. Instead of relying on traditional biological testing methods…

Continue Reading

TuesdayMay 19, 2026 1:58 pm

BioMedNewsBreaks — Oncotelic Therapeutics Inc. (OTLC) Expands Beyond Biotech with AI-Enhanced Robotics Strategy

Oncotelic Therapeutics (OTCQB: OTLC) is moving beyond its roots as a clinical-stage biotechnology company into the quickly expanding intersection of artificial intelligence and industrial automation. “Through two closely aligned announcements, the firm has unveiled a strategic partnership with TechForce Robotics, which positions it to commercialize a next-generation, AI-enhanced platform created for regulated pharmaceutical environments,” reads a recent article. “At the core of this pivot is Oncotelic’s proprietary PDAOAI platform, an AI-driven system designed to improve compliance, monitoring, and operational intelligence. By integrating this innovation with TechForce Robotics’ hardware and manufacturing expertise, the companies aim to deliver a GMP-compliant robotics solution capable…

Continue Reading